Smith & Nephew plc (SNN), a United Kingdom-based medical devices manufacturer, displayed strong revenue performance in the first quarter of 2023. Following the announcement of a 12-point plan to boost the delivery of its Strategy for Growth and advance into the higher-growth territory, SNN is making good progress. The company is reaffirming its commitment to top-line growth and margin advancement through impressive product launches.
This resulted in a buoyant stock price, which closed the last trading session significantly above its 50-day and 200-day moving averages of $29.42 and $26.77, respectively. To gain further insights into SNN's long-term growth potential, let us take a closer look at some key metrics.
